bit.bio launches ioScreen CRISPR screening service for human iPSC-derived cell models

• bit.bio launched ioScreen, a CRISPR screening service aimed at speeding drug discovery using human cell models.
• Service targets pharma and biotech groups lacking in-house screening capacity, positioning bit.bio to capture outsourced R&D budgets.
• Offering broadens the revenue mix beyond cell products, strengthening differentiation around human-relevant data early in target selection.
• Launch coincided with leadership expansion as Sejla Salic-Hainzl became the company’s first chief technology officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bit.bio Ltd. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.